Kelowna, British Columbia–(Newsfile Corp. – November 4, 2025) – Rize Oncology Inc. (OTC: RZONF) (the “ Company “), a clinical-stage pharmaceutical company focused on developing innovative oncology therapeutics, is pleased to announce that on October 30, 2025 it completed a non-brokered private placement (the “ Private Placement “) of units of the Company (the “ Units “), raising gross proceeds of C$500,000.

The Private Placement consisted of the issuance of 5,000,000 Units at a price of C$0.10 per Unit, for gross proceeds of C$500,000. Each Unit is comprised of one common share in the capital of the Company (a “ Common Share “) and one Common Share purchase warrant (each, a “ Warrant “). Each Warrant entitles the holder to acquire one additional Common Share at a price of C$0.30

See Full Page